Journal Reviews

Outcomes of sarcomatoid differentiation in urothelial carcinoma

5 December 2022 | | Urologic Oncology | #BladderCancer, #scmsm, #uroonc, bladder cancer, neoadjuvant therapy, pathological outcomes, sarcomatoid differentiation, survival, urothelial carcinoma

Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | Urologic Oncology | #BladderCancer, #blcsm, cytosine arabinoside, intravesical therapy, mitomycin C, non-muscle-invasive bladder cancer, randomised trial, #uroonc, urinary pH

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

BJUI International journal cover image.

BCG after TURBT – does timing matter?

2 March 2022 | | Urologic Oncology | #BladderCancer, #blcsm, #uroonc, BCG-unresponsive, bacille Calmette-Guérin, bladder cancer, intravesical therapy, transurethral resection of bladder tumour

Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...

BJUI International cover photo

Non-urothelial tumours of bladder – impact on oncological outcomes

9 March 2020 | | Urologic Oncology | #BladderCancer, #blcsm, non-urothelial, radical cystectomy, variant histology

Non-urothelial bladder tumours are not very common and they are generally considered to be high risk tumours when compared to standard urothelial tumours. In this study the researchers analysed the oncological outcomes of patients with such histology in comparison to...

Repeat transurethral resection in non-muscle invasive bladder cancer

1 November 2018 | | Uroradiology | Bladder, Cancer, Detrusor, Muscle, Progression, Re-resection, Recurrence, Upstaging

The authors felt this is a big problem because there is no standardised practice on re-resection following initial transurethral resection of bladder tumour (TURBT). Getting detrusor muscle in the first specimen is thought to be important. However muscle is not...

Predicting bone scan positivity in non-metastatic CRPC

1 May 2016 | | Urologic Oncology | Disease-Free Survival, Metastasis, Mortality, Prostate Cancer, Prostatectomy, Prostate Specific Antigen

There is evidence that suggests that early treatment with chemotherapy, immunotherapy or hormone therapy leads to a better response in patients with asymptomatic metastatic castrate resistant prostate cancer (CRPC). This study aimed to predict bone scan positivity in patients with...